Cargando…

Implementation of new endovenous treatments in therapy for lateral embryonic veins

Klippel-Trénaunay syndrome is characterized by a persistent lateral embryonic vein. This so-called marginal vein has a large diameter causing venous stasis and venous hypertension because of the absence of valves along its entire length. The extensive diameter of the vein impedes successful treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Huegel, Ulrike, Baumgartner, Iris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600075/
https://www.ncbi.nlm.nih.gov/pubmed/31304432
http://dx.doi.org/10.1016/j.jvscit.2018.12.016
_version_ 1783431042202337280
author Huegel, Ulrike
Baumgartner, Iris
author_facet Huegel, Ulrike
Baumgartner, Iris
author_sort Huegel, Ulrike
collection PubMed
description Klippel-Trénaunay syndrome is characterized by a persistent lateral embryonic vein. This so-called marginal vein has a large diameter causing venous stasis and venous hypertension because of the absence of valves along its entire length. The extensive diameter of the vein impedes successful treatment by sclerotherapy. Surgical removal is considered technically challenging for potential severe intraoperative blood loss due to the large perforators to the deep veins. Here we show that endovenous treatments (laser ablation, cyanoacrylate adhesive) might be feasible options in therapy for lateral embryonic veins.
format Online
Article
Text
id pubmed-6600075
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-66000752019-07-12 Implementation of new endovenous treatments in therapy for lateral embryonic veins Huegel, Ulrike Baumgartner, Iris J Vasc Surg Cases Innov Tech Case report Klippel-Trénaunay syndrome is characterized by a persistent lateral embryonic vein. This so-called marginal vein has a large diameter causing venous stasis and venous hypertension because of the absence of valves along its entire length. The extensive diameter of the vein impedes successful treatment by sclerotherapy. Surgical removal is considered technically challenging for potential severe intraoperative blood loss due to the large perforators to the deep veins. Here we show that endovenous treatments (laser ablation, cyanoacrylate adhesive) might be feasible options in therapy for lateral embryonic veins. Elsevier 2019-06-25 /pmc/articles/PMC6600075/ /pubmed/31304432 http://dx.doi.org/10.1016/j.jvscit.2018.12.016 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case report
Huegel, Ulrike
Baumgartner, Iris
Implementation of new endovenous treatments in therapy for lateral embryonic veins
title Implementation of new endovenous treatments in therapy for lateral embryonic veins
title_full Implementation of new endovenous treatments in therapy for lateral embryonic veins
title_fullStr Implementation of new endovenous treatments in therapy for lateral embryonic veins
title_full_unstemmed Implementation of new endovenous treatments in therapy for lateral embryonic veins
title_short Implementation of new endovenous treatments in therapy for lateral embryonic veins
title_sort implementation of new endovenous treatments in therapy for lateral embryonic veins
topic Case report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600075/
https://www.ncbi.nlm.nih.gov/pubmed/31304432
http://dx.doi.org/10.1016/j.jvscit.2018.12.016
work_keys_str_mv AT huegelulrike implementationofnewendovenoustreatmentsintherapyforlateralembryonicveins
AT baumgartneriris implementationofnewendovenoustreatmentsintherapyforlateralembryonicveins